Strategy for Depressing Antihypertensive Drugs in Very Elderly and Fragile Patients: A Review of Contemporary Data

Antihypertensive drugs reduce the risk of stroke and cardiovascular disease in all age groups. However, in elderly and frail patients, antihypertensive treatment is associated with an increased risk of hypotension, syncope, acute kidney injury and hyperkalemia; in these patients, the risk of AEs may outweigh the benefits of antihypertensive treatment, and drug withdrawal is proposed to reduce this risk. The concept of controlled withdrawal of antihypertensive drugs is new and many practical aspects require further study in randomized controlled trials to determine the longterm effects on important clinical outcomes and quality of life in elderly patients. Given the limited evidence on long-term outcomes of controlled withdrawal of antihypertensive drugs, it must be recognized that withdrawal of antihypertensive drugs is an area of limited evidence, with very few clinical trials assessing long-term clinical effects. This review examines the rationale and potential barriers to the implementation of controlled withdrawal of antihypertensive drugs in the elderly. Recommendations for identifying patients at high risk of adverse events and a deprescribing algorithm are provided.

1. United Nations, Department of Economic and Social Affairs. World Population Prospects the 2015 Revision: Key Findings and Advance Tables, New York. 2015; 66p.

2. Brent ME, Holly JM, Jan NB et al. Sutherland Managing Hypertension in Older Adults. Current Hypertension Reports. 2024; 26: 157–167. DOI: 10.1007/s11906-023-01289-7

3. Rahimi K, Bidel Z, Nazarzadeh M, et al. Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis. Lancet 2021; 398(10305): 1053–64. DOI: 10. 1016/S0140-6736(21)01921-8

4. Beckett NS, Peter R, Fletcher AE, et al. for the HYVET Study Group. Treatment of hypertension in patients 80 years of age and older. N Engl J Med; 2008; 358: 1887–1898. DOI: 10.1056/NEJMoa0801369

5. Pajewski NM, Berlowitz DR, Bress AP, et al. Intensive vs. standard blood pressure control in adults 80 years or older: A secondary analysis of the Systolic Blood Pressure Intervention Trial. J Am Geriatr Soc; 2020: 68: 496–504. Doi: 10.1111/jgs.16272

6. Zhang W, Zhang S, Deng Y, et al. Trial of intensive blood-pressure control in older adults with hypertension. N Engl J Med; 2021; 385: 1268–1279. DOI: 10.1056/NEJMoa2111437

7. Sheppard JP, Benetos A, Bogaerts J, et al. Strategies for Identifying Patients for Deprescribing of Blood Pressure. Current Hypertension Reports. 2024; 26: 225–236. DOI: 10.1007/s11906-024-01293-5.

8. Liau SJ, Zhao M, Hamada S, et al. Deprescribing Opportunities for Frail Residents of Nursing Homes: A Multicenter Study in Australia, China, Japan, and Spain. J Am Med Dir Assoc. 2024; 25(5): 876-883. DOI: 10.1016/j.jamda.2024.01.015.

9. Mancia G, Kreutz R, Brunström M, et al. ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH). J Hypertension. 2023; 41(12): 1874-2071. DOI: 10.1097/hjh.00000000003480.

10. Christiaens A, Henrard S, Sinclair AJ, et al. Deprescribing glucoselowering therapy in older adults with diabetes: a systematic review of recommendations. J Am Med Dir Assoc. 2023; 24(3): 400–2. DOI: 10.1016/j.jamda.2022.12.018.

11. Steinman MA, Landefeld CS. Overcoming Inertia to Improve Medication Use and Deprescribing. JAMA — J Am Med Assoc; 2018; 320(18): 1867–9. DOI: 10.1001/jama.2018.16473.

12. Gnjidic D, Johansson M, Meng DM, et al. Achieving sustainable healthcare through deprescribing. Cochrane Database Syst Rev. 2022; 10(10): Ed000159. DOI: 10.1002/14651858

13. Jing B, Liu X, Graham LA, et al. Deprescribing of Antihypertensive Medications and Cognitive Function in Nursing Home Residents. JAMA Intern Med. 2024; Nov 1;184(11):1347-1355. DOI: 10.1001/jamainternmed.2024.4851

14. Silva IM, Moreira PM , Santos AM, et al. Desprescribing antihypertensives in older people in primary care: subgroup analysis of the MINOR randomised clinical trial. Int J Clin Pharm. 2025; Feb;47(1):53-59. DOI: 10.1007/s11096-024-01805-y.

15. Odden MC, Graham LA, Liu X, e t al. Antihypertensive Deprescribing and Cardiovascular Events Among Long-Term Care Residents JAMA Netw Open. 2024 Nov 4; 7(11): e2446851. DOI: 10.1001/jamanetworkopen.2024.46851

16. Bogaerts J., Gussekloo J, Bianca EM, at al. Effects of the discontinuation of antihypertensive treatment on neuropsychiatric symptoms and quality of life in nursing home residents with dementia (DANTON): a multicentre, open-label, blinded-outcome, randomised controlled trial. Age and Ageing. 2024; 53: afae133. DOI: 10.1093/ageing/afae133

17. Brunner L, Rodondi N, Aubert CE. Barriers and facilitators to deprescrib ing of cardiovascular medications: a systematic review. BMJ Open. 2022; 12(12): e061686. DOI: 10.1136/bmjopen-2022-061686

18. Crutzen S, Baas G, Abou J, et al. Barriers and enablers of older patients to deprescribing of cardiometa bolic medication: a focus group study. Front Pharmacol. 2020; 11: 555327. DOI: 10.3389/fphar.2020.01268

19. Abou J, Crutzen S, Tromp V, et al. Barriers and enablers of healthcare providers to deprescribe cardiometabolic medication in older patients: a focus group study. Drugs Aging. 2022; 39(3): 209–21. DOI: 10.1007/s40266-021-0091

20. Seewoodharry M, Khunti K, Davies MJ, et al. Attitudes of older adults and their carers towards de-prescribing: a systematic review. Diabet Med. 2022; 39(7): e14801. DOI: 10.1111/dme.14801

21. Stuijt PJ, Liset van Dijk MH, Faber A, et al. Effects of a multicomponent communication training to involve older people in decisions to DEPRESCRIBE cardiometabolic medication in primary care (CO-EPRESCRIBE): protocol for a cluster randomized controlled trial with embedded process and economic evaluation. BMC Primary Care. 2024; 25: 210. DOI: 10.1186/s12875-024-02465-7

22. Scott IA, Le Couteur DG. Physicians need to take the lead in deprescribing. Intern Med J 2015; 45: 352-6. DOI: 10.1111/imj.12693

23. Albasri A, Hattle M, Koshiaris C, et al. Association between antihypertensive treatment and adverse events: systematic review and meta-analysis. BMJ (Clinical research ed). 2021; 372: 5. DOI: 10.1136/bmj.n189

24. Sheppard JP, Koshiaris C, Stevens R, et al. The association between antihypertensive treatment and serious adverse events by age and frailty: A cohort study. PLoS Med. 2023; 20(4): e1004223. DOI: 10.1371/journal.pmed.100422

25. Archer L, Koshiaris C, Lay-Flurrie S, et al. Development and external validation of a risk prediction model for falls in patients with an indication for antihypertensive treatment: retrospective cohort study. BMJ (Clinical research ed). 2022; 379: e070918. DOI: 10.1136/bmj-2022-070918

26. Groppelli A, Rivasi G, Fedorowski A, et al. Targets for deprescribing in patients with hypertension and reflex syncope. Eur J Intern Med. 2024; Oct: 128: 40-44. DOI: 10.1016/j.ejim.2024.05.014

27. O’Mahony D, Cherubini A, Guiteras AR, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 3. Eur Geriatr Med. 2023; Aug;14(4):625-632. DOI: 10.1007/s41999-023-00777-y.

28. Sychev D.A., Cherniaeva M.S., Rozhkova M.A., Vorobyova A.E. Potentially Inappropriate Medications for Use in Older Adults: Beers Criteria (2023 American Geriatrics Society Guidelines). Safety and Risk of Pharmacotherapy. 2024;12(3):253-267. https://doi.org/10.30895/2312-7821-2024-420. (In Russ.).